Home › Linfoma a cellule del mantello › California › Baldwin Park
Studi clinici su Linfoma a cellule del mantello a Baldwin Park, CA
15 studi su Linfoma a cellule del mantello cercano partecipanti presso sedi a Baldwin Park e dintorni (entro circa 30 miglia). Apri uno studio per vedere chi può partecipare e come contattare il team.
Testo ufficiale dello studio (inglese)
Stai reclutando per uno studio? Mettilo in evidenza in cima alla pagina — $99 per 30 giorni →
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
In reclutamentoFase 1
- City of Hope, Duarte · a 4 mi di distanza
Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy
In reclutamentoFase 2
- City of Hope Comprehensive Cancer Center, Duarte · a 4 mi di distanza
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
In reclutamentoFase 1/2
- City of Hope, Duarte · a 4 mi di distanza
Pacritinib in Combination With a BTK Inhibitor for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma
In reclutamentoFase 1
- City of Hope Medical Center, Duarte · a 4 mi di distanza
This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma
In reclutamentoFase 1
- City of Hope, Duarte · a 4 mi di distanza
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
In reclutamentoFase 1
- City of Hope, Duarte · a 4 mi di distanza
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
In reclutamentoFase 1/2
- City of Hope Medical center, Duarte · a 4 mi di distanza
Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
In reclutamentoFase 1
- City of Hope Medical Center, Duarte · a 4 mi di distanza
The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
In reclutamentoFase 1/2
- City of Hope, Duarte · a 4 mi di distanza
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
In reclutamentoFase 1
- City of Hope, Duarte · a 4 mi di distanza
Nemtabrutinib With Rituximab for the Treatment of Patients With Mantle Cell Lymphoma
In reclutamentoFase 2
- City of Hope Medical Center, Duarte · a 4 mi di distanza
Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma
In reclutamentoFase 1
- City of Hope Medical Center, Duarte · a 4 mi di distanza
Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
In reclutamentoFase 2
- City of Hope Medical Center, Duarte · a 4 mi di distanza
BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL
In reclutamentoFase 1
- City of Hope Medical Center, Duarte · a 4 mi di distanza
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
In reclutamentoStudio osservazionale
- Massive Bio SYNERGY-AI site, Duarte · a 4 mi di distanza
Studi su Linfoma a cellule del mantello in altre città
- Houston, TX15 studi
- Durham, NC13 studi
- New York City, NY12 studi
- Seattle, WA12 studi
- Milwaukee, WI12 studi
- Boston, MA11 studi
- Nashville, TN11 studi
- Columbus, OH11 studi
- Chicago, IL10 studi
- Rochester, MN9 studi
- Portland, OR9 studi
- Atlanta, GA8 studi
Altri studi a Baldwin Park
- Cancro al seno44 studi
- Leucemia mieloide acuta40 studi
- Cancro colorettale37 studi
- Cancro del polmone non a piccole cellule36 studi
- Cancro (tutti i tipi)34 studi
- Cancro alla prostata30 studi
- Cancro metastatico30 studi
- Sindromi mielodisplastiche26 studi
- Cancro ovarico25 studi
- Cancro ai polmoni24 studi
- Mieloma multiplo23 studi
- Cancro dello stomaco22 studi
Fonte: ClinicalTrials.gov, dati recuperati il 6 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.